NEW YORK (GenomeWeb News) — 454 Life Sciences today said third-quarter revenue increased 70 percent to $9.9 million from $5.8 million year over year.
The CuraGen subsidiary said 454 made $4.8 million from sales of instruments and reagents and $2.8 million from sequencing service revenue. The remainder came from grants and other sources, the company said.
CuraGen said it is still working with Goldman Sachs to review options for 454’s future. In August, GenomeWeb News reported that the company had hired Goldman Sachs to help it develop strategies for its stake in 454.